CN118908961A - 咪唑并二氮杂卓二酮和其使用方法 - Google Patents

咪唑并二氮杂卓二酮和其使用方法 Download PDF

Info

Publication number
CN118908961A
CN118908961A CN202410783264.2A CN202410783264A CN118908961A CN 118908961 A CN118908961 A CN 118908961A CN 202410783264 A CN202410783264 A CN 202410783264A CN 118908961 A CN118908961 A CN 118908961A
Authority
CN
China
Prior art keywords
optionally substituted
methyl
compound
chlorophenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410783264.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·丹尼尔斯
M·余
J-C·P·哈曼奇
T·T·狄碧奇
M·W·勒德贝尔
N·A·卡斯尔
G·马罗琦琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goldfinch Biology Co
Original Assignee
Goldfinch Biology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Biology Co filed Critical Goldfinch Biology Co
Publication of CN118908961A publication Critical patent/CN118908961A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN202410783264.2A 2018-03-05 2019-03-05 咪唑并二氮杂卓二酮和其使用方法 Pending CN118908961A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862638448P 2018-03-05 2018-03-05
US62/638448 2018-03-05
CN201980030356.0A CN112351781B (zh) 2018-03-05 2019-03-05 咪唑并二氮杂卓二酮和其使用方法
PCT/US2019/020732 WO2019173327A1 (en) 2018-03-05 2019-03-05 Imidazodiazepinediones and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980030356.0A Division CN112351781B (zh) 2018-03-05 2019-03-05 咪唑并二氮杂卓二酮和其使用方法

Publications (1)

Publication Number Publication Date
CN118908961A true CN118908961A (zh) 2024-11-08

Family

ID=67847465

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410783264.2A Pending CN118908961A (zh) 2018-03-05 2019-03-05 咪唑并二氮杂卓二酮和其使用方法
CN201980030356.0A Active CN112351781B (zh) 2018-03-05 2019-03-05 咪唑并二氮杂卓二酮和其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980030356.0A Active CN112351781B (zh) 2018-03-05 2019-03-05 咪唑并二氮杂卓二酮和其使用方法

Country Status (7)

Country Link
US (2) US11623930B2 (https=)
EP (1) EP3761989A4 (https=)
JP (2) JP7408557B2 (https=)
CN (2) CN118908961A (https=)
AU (2) AU2019231208B2 (https=)
CA (1) CA3093084A1 (https=)
WO (1) WO2019173327A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093084A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
CN115927202A (zh) * 2023-01-10 2023-04-07 北京爱思益普生物科技股份有限公司 一种trpc5突变细胞株及其构建方法和应用
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020460A1 (en) * 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
TW201444844A (zh) * 2013-03-14 2014-12-01 Hydra Biosciences Inc 經取代之黃嘌呤及使用其之方法
CN107082782B (zh) 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法
JP6667092B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
DK3652176T3 (da) 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
CA3093084A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
EP3917940A1 (en) * 2019-01-30 2021-12-08 Rothamsted Research Ltd Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy

Also Published As

Publication number Publication date
JP2024037971A (ja) 2024-03-19
US20210087200A1 (en) 2021-03-25
US20230365575A1 (en) 2023-11-16
AU2019231208B2 (en) 2025-01-23
JP7408557B2 (ja) 2024-01-05
EP3761989A4 (en) 2021-11-24
US11623930B2 (en) 2023-04-11
JP7809096B2 (ja) 2026-01-30
AU2025202716A1 (en) 2025-05-08
CN112351781A (zh) 2021-02-09
US12466834B2 (en) 2025-11-11
JP2021516225A (ja) 2021-07-01
WO2019173327A1 (en) 2019-09-12
AU2019231208A1 (en) 2020-09-17
CN112351781B (zh) 2024-07-02
CA3093084A1 (en) 2019-09-12
EP3761989A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7809096B2 (ja) イミダゾジアゼピンジオン及びその使用方法
US11046690B2 (en) Pyridazinones and methods of use thereof
CN113939295A (zh) 哒嗪酮及其使用方法
PT2663561E (pt) Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
TWI714528B (zh) 甲醯胺衍生物
MX2013003345A (es) Compuesto de amida sustituida.
CN114746149A (zh) 作为肝脏x受体激动剂的1,2,4-噁二唑衍生物
WO2019028308A1 (en) BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE
KR20190138824A (ko) 치환된 n-아릴에틸-2-아릴퀴놀린-4-카르복스아미드 및 그의 용도
HK40115225A (en) Pyridazinones and methods of use thereof
HK40056020A (en) Pyridazinones and methods of use thereof
HK40056020B (en) Pyridazinones and methods of use thereof
EA048445B1 (ru) Пиридазиноны и способы их применения
BR112015016433B1 (pt) Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination